Clinical Trial

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-05-13
notable Trial sites expanded: 0 -> 8 locations 2026-05-13
Trial Details
NCT Number NCT07502560
Lead Sponsor GlaxoSmithKline
Collaborators: Finnish Vaccine Research;, Dr Arto Palmu
Conditions Herpes Zoster
Enrollment 33,609 participants
Start Date 2026-03-31
Primary Completion 2030-04-01 (estimated)
Study Completion 2037-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-12